A Study of MEDI9253 in Combination With Durvalumab in Select Solid Tumors
- Inclusion Criteria: 1. Participant must be at least 18 years old at signing of informed consent. 2. Body weight > 35 kg at screening Exclusion Criteria: 1 Primary central nervous system (CNS) disease is excluded, as well as untreated or uncontrolled metastatic CNS involvement, leptomeningeal disease, or cord compression. NOTE: CNS disease that has been treated and stable/controlled for at least 3 months is permitted. Participants with CNS disease controlled via systemic steroids are not permitted.
Up to approximately 192 participants may be assigned to study intervention in the study
across approximately 30 sites globally.
Trial Phase Phase I
Trial Type Treatment
AstraZeneca Pharmaceuticals LP
- Primary ID D7880C00001
- Secondary IDs NCI-2020-13138
- Clinicaltrials.gov ID NCT04613492